Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) FCF Margin (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed FCF Margin for 6 consecutive years, with 2328.56% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin fell 148031.0% to 2328.56% in Q4 2025 year-over-year; TTM through Dec 2025 was 597.64%, a 15717.0% decrease, with the full-year FY2025 number at 597.64%, down 15717.0% from a year prior.
  • FCF Margin was 2328.56% for Q4 2025 at Kymera Therapeutics, down from 987.37% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 7.48% in Q4 2023 to a low of 2328.56% in Q4 2025.
  • A 5-year average of 539.13% and a median of 366.05% in 2022 define the central range for FCF Margin.
  • Biggest YoY gain for FCF Margin was 34919bps in 2025; the steepest drop was -148031bps in 2025.
  • Kymera Therapeutics' FCF Margin stood at 254.36% in 2021, then increased by 3bps to 247.28% in 2022, then surged by 97bps to 7.48% in 2023, then tumbled by -11246bps to 848.26% in 2024, then plummeted by -175bps to 2328.56% in 2025.
  • Per Business Quant, the three most recent readings for KYMR's FCF Margin are 2328.56% (Q4 2025), 987.37% (Q3 2025), and 527.88% (Q2 2025).